07:00 , Aug 13, 2007 |  BioCentury  |  Finance

Ebb & Flow

A pair of high-profile setbacks among two of Germany's late-stage biotech companies has left the country's biotech industry with only a handful of Phase III products. Thus, investors are starting to view the German landscape...
08:00 , Nov 1, 2004 |  BioCentury  |  Strategy

Biomarker deals

Biomarker deals Caprion Partner Deal description Date Sunol Molecular Caprion received rights to develop antibodies in Phase I for hemolytic uremic syndrome (HUS) resulting from E. coli infection 6/14/04 Abbott To discover antibody targets for...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

Beyond Genomics scientific advisory board update

Beyond Genomics Inc. , Waltham, Mass.   Business: Cardiovascular, Cancer, Neurology   Appointed: Arnold Levine, professor at The Cancer Institute of New Jersey, as co-chair; Jeffrey Friedman, director of the Starr Center for Human Genetics...
07:00 , Jun 21, 2004 |  BC Week In Review  |  Company News

Beyond Genomics management update

Beyond Genomics Inc. , Waltham, Mass.   Business: Cardiovascular, Cancer, Neurology   Hired: Stephen Martin as SVP and CTO, formerly senior director of the Discovery Proteomics & Small Molecule Research Center at Applied Biosystems Group...
08:00 , Mar 8, 2004 |  BC Week In Review  |  Company News

Beyond Genomics board of directors update

Beyond Genomics Inc. , Waltham, Mass.   Business: Cardiovascular, Cancer, Neurological   Appointed: Stelios Papadopoulos, vice chairman of SG Cowen Securities Corp.  ...
08:00 , Feb 9, 2004 |  BC Week In Review  |  Company News

Beyond Genomics, AstraZeneca deal

Beyond Genomics will use its systems biology platform and BioSystematics informatics tools to identify biomarkers of drug-induced toxicity for AZN. Beyond Genomics' technology analyzes and integrates transcript, protein and metabolite data. Beyond Genomics Inc. ,...
08:00 , Feb 3, 2004 |  BC Extra  |  Company News

Beyond Genomics, AZN toxicology deal

Beyond Genomics (Waltham, Mass.) will use its systems biology platform and BioSystematics informatics tools to identify biomarkers of drug-induced toxicity for AstraZeneca (LSE:AZN; AZN). Beyond Genomics' technology analyzes and integrates transcript, protein and metabolite data....
08:00 , Feb 2, 2004 |  BC Week In Review  |  Company News

Beyond Genomics, GlaxoSmithKline deal

GSK agreed to fund research by Beyond Genomics to identify biomarkers for metabolic diseases. Under the deal, Beyond Genomics receives an upfront fee and is eligible for milestones. Beyond Genomics also retains certain rights in...
08:00 , Jan 28, 2004 |  BC Extra  |  Company News

Beyond Genomics, GSK systems biology deal

GlaxoSmithKline (LSE:GSK; GSK) agreed to fund Beyond Genomics' systems biology research to identify biomarkers for metabolic diseases. Under the deal, Beyond Genomics receives an upfront fee, and is eligible for milestones. Beyond Genomics (Waltham, Mass.)...
08:00 , Mar 31, 2003 |  BC Week In Review  |  Company News

Beyond Genomics management update

Beyond Genomics Inc. , Waltham, Mass.   Business: Cardiovascular, Cancer, Neurological   Hired: Robert McBurney as SVP of R&D and CSO, formerly president and CEO of Differential Proteomics Inc.; and Paul Stroobant as VP of...